H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
18%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit

George B. Stefano, Kirk J. Mantione, Milena Králíčková, Radek Ptacek, Hana Kuzelova, Tobias Esch, Richard M. Kream

Med Sci Monit 2012; 18(8): RA133-137

DOI: 10.12659/MSM.883259

Published: 2012-08-01


Clinical observations stemming from widespread employment of restorative L-3,4-dihydroxyphenylalanine (L-DOPA) therapy for management of dyskinesia in Parkinson’s Disease (PD) patients implicate a regulatory role for endogenous morphine in central nervous system dopamine neurotransmission. Reciprocally, it appears that restorative L-DOPA administration has provided us with a compelling in vivo pharmacological model for targeting peripheral sites involved in endogenous morphine expression in human subjects. The biological activities underlying endogenous morphine expression and its interaction with its major precursor dopamine strongly suggest that endogenous morphine systems are reciprocally dysregulated in PD. These critical issues are examined from historical and current perspectives within our short review.

Keywords: Parkinson Disease - urine, Morphine - urine, Levodopa - therapeutic use, Humans, Codeine - urine, Animals, Tetrahydropapaveroline - urine



Back